Author

Yongkun Wei

The University of Texas MD Anderson Cancer CenterORCID 0000-0001-8998-5333Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Organism:mouse· 2 Assay:proteomics· 2 Approach:benchmark study· 1 Assay:clinical cohort / trial· 1

Frequent Co-Authors

Haoqiang YingiD· 3 shared Anirban MaitraiD· 2 shared Ching-Fei LiiD· 2 shared Han LiangiD· 2 shared Huamin WangiD· 2 shared Jun YaoiD· 2 shared Madelaine Skolastika TheardyiD· 2 shared Mitsunobu TakedaiD· 2 shared

Activity by Year

2024-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Haoqiang YingORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologyCancer ResearchPeer-reviewedSep 18, 2025

KRAS inhibition activates an actionable CD24 do-not-eat-me signal in pancreatic cancer

Yongkun Wei, Minghui Liu, Er-Yen Yen…·Haoqiang Ying

This study identifies CD24 as an actionable signal activated by KRASG12C inhibition in pancreatic cancer, enhancing macrophage phagocytosis and sensitizing tumors to therapy.

6 citations

mouseproteomics

𝕏 PostBluesky

Cancer BiologyCell Reports MedicinePeer-reviewedJul 25, 2025

Therapeutic targeting of Syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers

Madelaine Skolastika Theardy, Mitsunobu Takeda, Alexey V. Sorokin…·Wantong Yao

This study identifies the YAP1-SDC1 axis as a driver of resistance to mKRAS inhibitors in gastrointestinal cancers and suggests targeting this axis to overcome resistance.

6 citations

humanexperimental assay

𝕏 PostBluesky

Cancer BiologybioRxivPreprintOct 20, 2024

All-trans retinoic acid-mediated ADAR1 degradation synergizes with PD-1 blockade to suppress pancreatic cancer

Ching-Fei Li, Li‐Yuan Bai, Yongkun Wei…·Mien‐Chie Hung

This study shows that ATRA causes ADAR1 degradation and enhances PD-1 blockade to improve antitumor immunity and survival in pancreatic cancer.

6 citations

mousehuman

𝕏 PostBluesky